JP Morgan Chase’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-133,328
| Closed | -$493K | – | 5785 |
|
|
2017
Q4 | $493K | Buy |
133,328
+43,915
| +49% | +$180K | ﹤0.01% | 4067 |
|
|
2017
Q3 | $367K | Buy |
89,413
+88,083
| +6,623% | +$337K | ﹤0.01% | 3924 |
|
|
2017
Q2 | $5K | Sell |
1,330
-11,253
| -89% | -$44.6K | ﹤0.01% | 4772 |
|
|
2017
Q1 | $52K | Buy |
+12,583
| New | +$52.9K | ﹤0.01% | 4518 |
|
|
2016
Q2 | – | Sell |
-75,833
| Closed | -$577K | – | 5115 |
|
|
2016
Q1 | $577K | Sell |
75,833
-5,182
| -6% | -$39.9K | ﹤0.01% | 3303 |
|
|
2015
Q4 | $1.08M | Sell |
81,015
-13,190
| -14% | -$227K | ﹤0.01% | 3083 |
|
|
2015
Q3 | $1.55M | Sell |
94,205
-1,510
| -2% | -$31K | ﹤0.01% | 2875 |
|
|
2015
Q2 | $2.15M | Buy |
95,715
+1,332
| +1% | +$21.1K | ﹤0.01% | 2875 |
|
|
2015
Q1 | $923K | Sell |
94,383
-15,517
| -14% | -$152K | ﹤0.01% | 3263 |
|
|
2014
Q4 | $1.25M | Buy |
109,900
+64,150
| +140% | +$696K | ﹤0.01% | 3230 |
|
|
2014
Q3 | $527K | Buy |
+45,750
| New | +$699K | ﹤0.01% | 3645 |
|
|
2014
Q2 | – | Sell |
-5,918
| Closed | -$106K | – | 3690 |
|
|
2014
Q1 | $106K | Buy |
+5,918
| New | +$97.2K | ﹤0.01% | 3480 |
|
|
2013
Q4 | – | Sell |
-4,144
| Closed | -$51K | – | 4355 |
|
|
2013
Q3 | $51K | Sell |
4,144
-337,861
| -99% | -$3.56M | ﹤0.01% | 4258 |
|
|
2013
Q2 | $3.22M | Buy |
+342,005
| New | +$4.39M | ﹤0.01% | 2445 |
|
JP Morgan Chase's CASC Position: Q1 2018 in Review
JP Morgan Chase sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 133,328 shares — an estimated $493K sold.
JP Morgan Chase first reported a position in CASC in Q2 2013 and held it in 14 quarters. The position peaked at $3.22M in Q2 2013. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- JP Morgan Chase reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- JP Morgan Chase sold 133,328 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $493K.
- JP Morgan Chase first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 14 quarters.
- JP Morgan Chase's Cascadian Therapeutics, Inc. position peaked at $3.22M in Q2 2013.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on JP Morgan Chase's 13F filing for Q1 2018, filed 10 May 2018.